Leidos at Jefferies Global Industrials Conference 2026: growth broadens

Leidos raised full-year guidance after delivering 4% organic growth in Q2 and 5% in H1 2024, implying roughly 8% organic growth in H2 despite health-segment headwinds. Defense revenue rose 6% to $3.6 billion with a 2.2x book-to-bill ratio, while homeland revenue increased 32% (15% organically), supported by FAA work and the ENTRUST acquisition. The $2.4 billion ENTRUST deal doubles Leidos' energy-infrastructure business and expands its addressable market about threefold, aided by utility spending tied to AI and data-center power demand. Risks include a roughly 200bp H2 health-margin decline, the VBA contract recompete, potential $100 million-$150 million MHS GENESIS revenue reduction, and uncertain timing for FAA modernization awards.

Analysis

The investable issue is not the reported guidance raise but whether the earnings mix can sustain a rerating from legacy federal-services multiples toward defense technology and utility-infrastructure peers. LDOS has multiple potential margin-accretive vectors—production scale in air defense, higher-margin homeland work, and engineering productivity in energy infrastructure—but its enterprise margin bridge is exposed to health profitability rolling over before these offsets mature. That creates a likely 1-3 month setup in which contract headlines drive the stock while underlying EPS revisions remain constrained.

The health recompete is materially asymmetric despite management’s confidence: vendor consolidation could preserve or expand share, but a lower-price procurement would reset the franchise’s economic value even if revenue retention is high. Separately, direct software licensing by the government would reduce reported revenue with limited EBIT damage, creating a possible headline-driven buying opportunity only if segment profit and free-cash-flow conversion remain intact. ORCL is the cleaner beneficiary if agencies increasingly unbundle licenses from systems integrators, although the dollar exposure described here is not itself thesis-moving for ORCL.

ENTRUST makes LDOS an indirect beneficiary of data-center power demand, but this exposure is engineering-services revenue rather than regulated utility earnings; DUK’s capital plan is more directly levered to load growth, while LDOS bears integration, labor utilization, and project-execution risk. The article contains internally stale financial periods despite a 2026 dateline, so the stated valuation and guidance cannot support an immediate fundamental position without current consensus EPS, backlog conversion, and award-status verification. The contrarian view is that investors may over-credit a broad defense/AI-infrastructure narrative before contract awards enter funded backlog and before health-margin normalization is fully reflected in estimates.

Key Decisions for Investors

• Place LDOS on an event-driven long watchlist, not an immediate core long: initiate only after verifying current-year consensus EPS and funded backlog, with a favorable trigger being FAA or maritime awards plus no reduction in health EBIT guidance. Target 10-15% upside over 6-12 months versus 7-10% downside if the VBA RFP confirms aggressive price-based consolidation.
• Use a 1-3 month LDOS / BAH relative-value screen around the VBA RFP and FAA decision. Go long LDOS versus short BAH only if LDOS’s health-profit risk is priced into estimates while an award adds funded backlog; avoid the pair if LDOS trades at a premium despite lower enterprise-margin guidance.
• Treat any announced MHS GENESIS revenue reduction as a potential buy-the-dip catalyst only if management quantifies immaterial EBIT and free-cash-flow impact. A material cut to segment profit, rather than revenue alone, falsifies this view.
• Maintain DUK as the cleaner public-market expression of sustained data-center load growth; do not extrapolate LDOS’s engineering opportunity into a utility-equity thesis. Reassess both if utility capex plans or interconnection demand weaken over the next two quarterly reporting cycles.